Blog
RSS FeedPosted by Michael Wonder on 08 Mar 2021
Department of Health publishes Public Summary Document for medicine without a published outcome
8 March 2021 - The Department of Health has published a Public Summary Document for mometasone furoate with indacaterol maleate ...
Posted by Michael Wonder on 08 Mar 2021
More startling revelations from the Public Summary Document for upadacitinib monohydrate (Rinvoq)
8 March 2021 - Take a seat before reading any further. ...
Posted by Michael Wonder on 14 Feb 2021
The future of drug pricing transparency
11 February 2021 - A federal “Transparency in Coverage” rule requires insurers to disclose list prices and historical net prices for ...
Posted by Michael Wonder on 04 Feb 2021
EMA COVID-19 assessments ‘OPEN’ to non-EU regulators
4 February 2021 - EMA is piloting a new ‘OPEN’ initiative to increase international collaboration on the evaluation of COVID-19 vaccines ...
Posted by Michael Wonder on 01 Feb 2021
Patient advocate slams cancer agency report over 'wall of silence' on PHARMAC funding
2 February 2021 - The Cancer Control Agency has released its first report into cancer in New Zealand, but one patient ...
Posted by Michael Wonder on 20 Jan 2021
2021 April price disclosure cycle – indicative prices
20 January 2021 - Indicative 1 April 2021 prices resulting from the 2021 April Cycle of Price Disclosure have now been ...
Posted by Michael Wonder on 12 Nov 2020
PHARMAC won’t release the data that changed its mind on diabetes
13 November 2020 - Diabetes Foundation Aotearoa will request the Ombudsman investigate the refusal by PHARMAC to release public submissions ...
Posted by Michael Wonder on 31 Oct 2020
Extra transparency measures for COVID-19 vaccines and therapeutics
30 October 2020 - Today the EMA has implemented two further extra transparency measures for COVID-19 medicines, by publishing both ...
Posted by Michael Wonder on 29 Oct 2020
Price transparency press call remarks by Administrator Seema Verma
29 October 2020 - Today’s price transparency announcement marks the culmination of four years of groundbreaking reforms. ...
Posted by Michael Wonder on 29 Oct 2020
White House to require insurers to post negotiated prices for medical care
29 October 2020 - Rule calls for gradually increasing disclosure requirements through 2024; health insurers say move could hurt competition, drive ...
Posted by Michael Wonder on 09 Oct 2020
New transparency measures for prescription medicines
9 October 2020 - The Australian Government has given approval to proceed with two measures to enhance transparency for prescription ...
Posted by Michael Wonder on 06 Oct 2020
FDA discloses vaccine guidelines blocked by White House
7 October 2020 - The FDA has laid out its safety standards for developers of COVID-19 vaccines after the White House ...
Posted by Michael Wonder on 06 Oct 2020
1 October 2020 price disclosure - confirmed prices
6 October 2020 - Confirmed 1 October 2020 prices resulting from the 2020 October Cycle of Price Disclosure has now been ...
Posted by Michael Wonder on 05 Oct 2020
EU regulators fully uphold transparency and independence standards for COVID-19 treatments and vaccines
5 October 2020 - The EMA has re-affirmed today that it will uphold its long-standing commitment to independence and transparency ...
Posted by Michael Wonder on 29 Sep 2020
Increase transparency at the FDA: we need sunlight to fight the pandemic
29 September 2020 - The FDA has issued a number of contentious decisions during the COVID-19 pandemic related to investigational ...